The study was designed to systematically investigate whether PD-1/PD-L1 inhibitors (atezolizumab, avelumab, durvalumab, nivolumab, pembrolizumab) improved the QoL of patients with NSCLC compared to chemotherapy based on published randomized controlled trials. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.